Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179715 | 1.00 | GRM1 (0.48) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL1110989 | 1.00 | GRM1 (0.48) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL7864721 | 0.90 | GRM1 (0.45) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL2587696 | 0.90 | GRM1 (0.45) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL9578970 | 0.90 | GRM1 (0.45) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL7331719 | 0.90 | GRM1 (0.45) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL669743 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL17064232 | 0.72 | FFAR3 (0.36) | GRM1SLC1A2SLC1A1FFAR3SLC7A5 | |
| SCHEMBL23817767 | 0.70 | — | — | |
| SCHEMBL85506 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0363994-B1 | (2R,3S,4S)-ALPHA-(CARBOXYCYCLOPROPYL)GLYCINE | SUNTORY LIMITED (JP) | 1993-09-22 | — | — | EP | claimed |
| US-5068412-A | Nervous system disorders such as treatment of epilepsy or Huntington's chorea | SUNTORY LIMITED (JP) | 1991-11-26 | — | — | US | claimed |
| EP-0363994-A2 | (2R,3S,4S)-alpha-(carboxycyclopropyl)glycine | SUNTORY LIMITED (JP) | 1990-04-18 | — | — | EP | claimed |
| US-20120258998-A1 | Fusion genes in gastrointestinal cancer | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-10-11 | — | — | US | disclosed |
| US-7666906-B2 | β-Benzyloxyaspartate derivatives with amino group on benzene ring | SUNTORY HOLDINGS LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7365091-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20070238783-A1 | Beta-benzyloxyaspartate derivatives with amino group on benzene ring | SUNTORY HOLDINGS LIMITED (JP) | 2007-10-11 | — | — | US | disclosed |
| US-7247652-B2 | β-benzyloxyaspartate derivatives with amino group on benzene ring | SUNTORY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| US-20040242652-A1 | Beta benzyloxyaspartate derivatives with amino group on benzene ring | SUNTORY HOLDINGS LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-0363994-B1 | (2R,3S,4S)-ALPHA-(CARBOXYCYCLOPROPYL)GLYCINE | SUNTORY LIMITED (JP) | 1993-09-22 | — | — | EP | disclosed |
| US-5068412-A | Nervous system disorders such as treatment of epilepsy or Huntington's chorea | SUNTORY LIMITED (JP) | 1991-11-26 | — | — | US | disclosed |
| US-5068412-A | Nervous system disorders such as treatment of epilepsy or Huntington's chorea | SUNTORY LIMITED (JP) | 1991-11-26 | — | — | US | disclosed |
| US-5068412-A | Nervous system disorders such as treatment of epilepsy or Huntington's chorea | SUNTORY LIMITED (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0363994-A3 | (2R,3S,4S)-ALPHA-(CARBOXYCYCLOPROPYL)GLYCINE | SUNTORY LIMITED (JP) | 1991-03-27 | — | — | EP | disclosed |
| EP-0363994-A3 | (2R,3S,4S)-ALPHA-(CARBOXYCYCLOPROPYL)GLYCINE | SUNTORY LIMITED (JP) | 1991-03-27 | — | — | EP | disclosed |
| EP-0363994-A2 | (2R,3S,4S)-alpha-(carboxycyclopropyl)glycine | SUNTORY LIMITED (JP) | 1990-04-18 | — | — | EP | disclosed |
| EP-0363994-A2 | (2R,3S,4S)-alpha-(carboxycyclopropyl)glycine | SUNTORY LIMITED (JP) | 1990-04-18 | — | — | EP | disclosed |
| EP-0363994-A2 | (2R,3S,4S)-alpha-(carboxycyclopropyl)glycine | SUNTORY LIMITED (JP) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | GRM1 1028/4885GRM5 710/4885GRM2 899/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | GRM1 956/4885GRM5 663/4885GRM2 871/4885 |
| US-20070238783-A1 | Beta-benzyloxyaspartate derivatives with amino group on benzene ring | SLC1A5, SLC7A1, SLC1A1 | GRM1 240/4885GRM5 390/4885GRM2 274/4885 |
| US-20040242652-A1 | Beta benzyloxyaspartate derivatives with amino group on benzene ring | SLC1A5, SLC1A1, SLC7A1 | GRM1 183/4885GRM5 326/4885GRM2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.